These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9154345)

  • 1. Effect of L-dopa alone and with benserazide on the spontaneous activity of striatal neurones in normal and 6-hydroxydopamine-lesioned rats.
    Chang WY; Webster RA
    Br J Pharmacol; 1997 May; 121(2):331-7. PubMed ID: 9154345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats.
    Ren T; Yang X; Wu N; Cai Y; Liu Z; Yuan W
    Neurosci Lett; 2011 Sep; 502(2):117-22. PubMed ID: 21835223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats.
    Adams CE; Hoffman AF; Hudson JL; Hoffer BJ; Boyson SJ
    Exp Neurol; 1994 Dec; 130(2):261-8. PubMed ID: 7867755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
    Carta AR; Pinna A; Cauli O; Morelli M
    Synapse; 2002 Jun; 44(3):166-74. PubMed ID: 11954048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A; Fenu S; Morelli M
    Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benserazide dosing regimen affects the response to L-3,4-dihydroxyphenylalanine in the 6-hydroxydopamine-lesioned rat.
    Tayarani-Binazir KA; Jackson MJ; Strang I; Jairaj M; Rose S; Jenner P
    Behav Pharmacol; 2012 Apr; 23(2):126-33. PubMed ID: 22236652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.
    Carta AR; Tabrizi MA; Baraldi PG; Pinna A; Pala P; Morelli M
    Exp Neurol; 2003 Dec; 184(2):679-87. PubMed ID: 14769359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats.
    Shen H; Kannari K; Yamato H; Arai A; Matsunaga M
    Tohoku J Exp Med; 2003 Mar; 199(3):149-59. PubMed ID: 12703659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expression of the calcium binding protein calretinin in the rat striatum: effects of dopamine depletion and L-DOPA treatment.
    Mura A; Feldon J; Mintz M
    Exp Neurol; 2000 Aug; 164(2):322-32. PubMed ID: 10915571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
    Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
    Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
    Cenci MA; Lee CS; Björklund A
    Eur J Neurosci; 1998 Aug; 10(8):2694-706. PubMed ID: 9767399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA.
    Darmopil S; Muñetón-Gómez VC; de Ceballos ML; Bernson M; Moratalla R
    Eur J Neurosci; 2008 Feb; 27(3):580-92. PubMed ID: 18279311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment.
    Bilbao G; Ruiz-Ortega JA; Miguens N; Ulibarri I; Linazasoro G; Gómez-Urquijo S; Garibi J; Ugedo L
    Brain Res; 2006 Apr; 1084(1):175-84. PubMed ID: 16574080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Johansson PA; Andersson M; Andersson KE; Cenci MA
    Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired behavioural and molecular adaptations to dopamine denervation and repeated L-DOPA treatment in Nur77-knockout mice.
    St-Hilaire M; Bourhis E; Lévesque D; Rouillard C
    Eur J Neurosci; 2006 Aug; 24(3):795-805. PubMed ID: 16930409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA.
    Alam M; Mayerhofer A; Schmidt WJ
    Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-3,4-dihydroxyphenylalanine-induced c-Fos expression in the CNS under inhibition of central aromatic L-amino acid decarboxylase.
    Shimamura M; Shimizu M; Yagami T; Funabashi T; Kimura F; Kuroiwa Y; Misu Y; Goshima Y
    Neuropharmacology; 2006 Jun; 50(8):909-16. PubMed ID: 16504219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.